Ropeg 3 Year Follow-Up vs. Hydroxyurea, MPNs in Patients Under the Age of 25 at Diagnosis, Targeting the JAK2 Mutation with Interferon and Arsenic
Second in ASH 2018 Series
by David Wallace
Dr Jean Jacques Kiladjian, Professor of Clinical Hematology, Hopital Saint-Louis, Paris, France interviews with David Wallace, PV Reporter at ASH 2018. Discussing Ropeg 3 year follow up vs. Hydroxyurea, MPNs in patients under the age of 25 at diagnosis, targeting the JAK2 mutation with Interferon and Arsenic.